Forecasting, insights and analytics is a strategic decision-making function within global product strategy and commercial departments in pharmaceutical companies. Unlike operational or sales-focused functions, these teams are responsible for maintaining objectivity in long-term forecasting accuracy and commercial planning for pharma products. This conference will explore how pharma organizations are using advanced analytics, AI and Real-World-Evidence to improve forecasting assumptions, suppo

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a multi-modality specialty pharma CDMO, and Formycon AG (FSE: FYB, Prime Standard, "Formycon"), an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabiliti

Insilico Medicine (“Insilico”, 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited (“CMS”, 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system

FUJIFILM Biotechnologies (Fujifilm), a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced that its commercial-scale cell culture manufacturing facility in Holly Springs, North Carolina, has been selected as one of only seven participants in the U.S. Food and Drug Administration’s (FDA) PreCheck Pilot Program. The program is a strategic initiative designed to strengthen America’s pharmaceutical m

Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substanti

Alamar Biosciences, Inc., a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™ Neuro 220 multiplexed panel kits, immediately deployable on the entire installed base of ARGO™ HT instruments, and as a single-plex assay through the company’s Technology Access Program (TAP). The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau

Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc., for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in the U.S. and

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease-agnostic, vision-restoring therapies for patients with photoreceptor loss due to retinal degeneration, today announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope’s lead optogenetic gene therapy, MCO-010. Under the expanded partnershi

SK bioscience announced that it will lead the Research Optimization & Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the Gates Foundation, establishing a global collaboration framework. The project is expected to involve technical collaboration with global health nonprofit PATH, and global technology consulting firm Slalom. ROTOR is designed to build a platform that leverages AI

Lonza has acquired the rights to Nona Biosciences’ transferrin receptor (TfR1) blood-brain barrier (BBB) technology and has expanded its strategic collaboration with the company to develop next-generation BBB delivery technologies. Under the agreement, Lonza will immediately offer the technology to developers of central nervous system (CNS) therapies while continuing to work with Nona on future BBB delivery solutions. The blood-brain barrier protects the brain by preventing ma